Skip to main content
SpringerLink
Log in

Systemische Therapie des metastasierten Blasenkarzinoms

Systemic therapy of metastatic bladder cancer

  • Leitthema
  • Published:
Der Urologe Aims and scope Submit manuscript

Zusammenfassung

In dieser Übersichtsarbeit werden die aktuellen medikamentösen Therapieoptionen beim metastasierten Urothelkarzinom der Harnblase vorgestellt. Neben den Standardtherapien werden neue Therapieansätze diskutiert und bewertet, die in den letzten Jahren publiziert oder auf Kongressen vorgestellt wurden.

Abstract

This review focuses on current options in the medical therapy of metastasized urothelial carcinoma of the bladder. Standard treatments as well as new, recently published therapeutic approaches are evaluated and discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Albers P, Park SI, Niegisch G et al (2011) Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99]. Ann Oncol 22:288–294

    Article  PubMed  CAS  Google Scholar 

  2. Bachner M, De Santis M (2009) Second-line therapy in bladder cancer. Curr Opin Urol 19:533–539

    Article  PubMed  Google Scholar 

  3. Bajorin DF, Dodd PM, Mazumdar M et al (1999) Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 17:3173–3181

    PubMed  CAS  Google Scholar 

  4. Balducci L, Extermann M (2000) Management of cancer in the older person: a practical approach. Oncologist 5:224–237

    Article  PubMed  CAS  Google Scholar 

  5. Bellmunt J, Choueiri TK, Fougeray R et al (2010) Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol 28:1850–1855

    Article  PubMed  Google Scholar 

  6. Bellmunt J, Fougeray R, Rosenberg JE et al (2013) Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy. Ann Oncol 24:1466–1472

    Article  PubMed  CAS  Google Scholar 

  7. Bellmunt J, Theodore C, Demkov T et al (2009) Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 27:4454–4461

    Article  PubMed  CAS  Google Scholar 

  8. Bellmunt J, Von Der Maase H, Mead GM et al (2012) Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol 30:1107–1113

    Article  PubMed  CAS  Google Scholar 

  9. Braguer D, Barret JM, Mcdaid H et al (2008) Antitumor activity of vinflunine: effector pathways and potential for synergies. Semin Oncol 35:13–21

    Article  Google Scholar 

  10. Dash A, Galsky MD, Vickers AJ et al (2006) Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer 107:506–513

    Article  PubMed  CAS  Google Scholar 

  11. De Santis M, Albers P, Bokemeyer C (2012) Erstlinienchemotherapie beim Harnblasenkarzinom. Der Onkologe 18:1012–1017

    Article  Google Scholar 

  12. De Santis M, Bellmunt J, Mead G et al (2009) Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer „unfit“ for cisplatin-based chemotherapy: phase II–results of EORTC study 30986. J Clin Oncol 27:5634–5639

    Article  Google Scholar 

  13. Edeline J, Loriot Y, Culine S et al (2012) Accelerated MVAC chemotherapy in patients with advanced bladder cancer previously treated with a platinum-gemcitabine regimen. Eur J Cancer 48:1141–1146

    Article  PubMed  CAS  Google Scholar 

  14. Fechner G, Siener R, Reimann M et al (2006) Randomised phase II trial of gemcitabine and paclitaxel second-line chemotherapy in patients with transitional cell carcinoma (AUO Trial AB 20/99). Int J Clin Pract 60:27–31

    Article  PubMed  CAS  Google Scholar 

  15. Gerullis H, Otto T, Ecke TH (2012) Targeted agents in second-line bladder cancer therapy. Anticancer Drugs 23:1003–1015

    Article  PubMed  CAS  Google Scholar 

  16. Hahn NM, Stadler WM, Zon RT et al (2011) Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04–75. J Clin Oncol 29:1525–1530

    Article  PubMed  CAS  Google Scholar 

  17. Han KS, Joung JY, Kim TS et al (2008) Methotrexate, vinblastine, doxorubicin and cisplatin combination regimen as salvage chemotherapy for patients with advanced or metastatic transitional cell carcinoma after failure of gemcitabine and cisplatin chemotherapy. Br J Cancer 98:86–90

    Article  PubMed  CAS  Google Scholar 

  18. Iyer G, Hanrahan AJ, Milowsky MI et al (2012) Genome sequencing identifies a basis for everolimus sensitivity. Science 338:221

    Article  PubMed  CAS  Google Scholar 

  19. Milowsky MI, Iyer G, Regazzi AM et al (2013) Phase II study of everolimus in metastatic urothelial cancer. BJU Int 112(4):462–470

    Article  PubMed  CAS  Google Scholar 

  20. Pagliaro L, Munsell M, Harris D et al (2013) Gemcitabine, paclitaxel, and doxorubicin as first-line therapy for patients with advanced urothelial carcinoma and renal insufficiency: a phase II study. J Clin Oncol 31:4528

    Google Scholar 

  21. Petros Grivas, Neeraj Agarwal, Arlene O. Siefker-Radtke et al (2012) Randomized phase II trial of gemcitabine/cisplatin (GC) with or without cetuximab (CET) in patients (pts) with advanced urothelial carcinoma (UC). J Clin Oncol 30(Suppl):4506

    Google Scholar 

  22. Seront E, Rottey S, Sautois B et al (2012) Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers. Ann Oncol 23:2663–2670

    Article  PubMed  CAS  Google Scholar 

  23. Sonpavde G, Pond GR, Fougeray R et al (2013)Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials. Eur Urol 63:717–723

    Article  PubMed  Google Scholar 

  24. Sonpavde G, Sternberg CN, Rosenberg JE et al (2010) Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium. Lancet Oncol 11:861–870

    Article  PubMed  CAS  Google Scholar 

  25. Stenzl A, Witjes JA, Compérat E et al (2012) Guidelines on bladder cancer muscle-invasive and metastatic (Euro Assoc Urol). Actas Urol Esp 36:449–460

    Article  PubMed  CAS  Google Scholar 

  26. Sternberg CN, De Mulder P, Schornagel JH et al (2006) Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer 42:50–54

    Article  PubMed  CAS  Google Scholar 

  27. Sternberg CN, De Mulder PH, Schornagel JH et al (2001) Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol 19:2638–2646

    PubMed  CAS  Google Scholar 

  28. Urakami S, Fujii Y, Yamamoto S et al (2013) Phase II trial of first-line chemotherapy with gemcitabine, etoposide, and cisplatin for patients with advanced urothelial carcinoma. Urol Oncol 90(2):179–183

    Google Scholar 

  29. Von Der Maase H, Sengelov L, Roberts JT et al (2005) Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23:4602–4608

    Article  Google Scholar 

Download references

Einhaltung ethischer Richtlinien

Interessenkonflikt. M. Retz, S.C. Schmid, M.W. und Kramer und A.S. Merseburger geben an, dass kein Interessenkonflikt besteht. Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.

Author information

Authors and Affiliations

  1. Urologische Klinik und Poliklinik, Klinikum rechts der Isar, Technische Universität München, Ismaninger Straße 22, 81675, München, Deutschland

    M. Retz & S.C. Schmid

  2. Klinik für Urologie und Urologische Onkologie, Medizinische Hochschule Hannover, Hannover, Deutschland

    M.W. Kramer & A.S. Merseburger

Authors
  1. M. Retz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S.C. Schmid
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M.W. Kramer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A.S. Merseburger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Retz.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Retz, M., Schmid, S., Kramer, M. et al. Systemische Therapie des metastasierten Blasenkarzinoms. Urologe 52, 1541–1546 (2013). https://doi.org/10.1007/s00120-013-3250-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00120-013-3250-1

Schlüsselwörter

Keywords

Search

Navigation